SCI TRANSL MED:过敏性哮喘由过敏原特异性CD4+T细胞对炎症反应决定

2016-10-08 xing.T MedSci原创

该研究的数据表明,过敏性哮喘的发展依赖于抗原特异性CD4 + T细胞的对固有2型介质的反应性以及增加平滑肌和气道上皮细胞对2型炎症反应的敏感性。

尽管全身致敏,但并非所有暴露于空气中过敏原的过敏患者都会发展成哮喘患者,明确导致过敏性个体发展成哮喘患者的影响因素能够指导哮喘治疗,并确定新的治疗靶点。近日,《Science Translational Medicine》杂志发表了来自美国波士顿马萨诸塞州总医院免疫和炎症疾病中心Josalyn L. Cho医生及其团队的研究文章,旨在明确影响过敏性个体发展成哮喘的因素。

研究者采用节段性变应原刺激过敏性哮喘患者(AA)和过敏性非哮喘对照者(AC)来确定气道免疫反应或促进哮喘发展的气道结构细胞是否有差异。研究者发现这两个群体都对过敏原产生过敏性气道炎症反应,然而,哮喘患者招募到气道的抗原特异性CD4+T细胞上固有2型受体表达显著增加,而且AA患者气道内2型细胞因子水平、总粘蛋白以及MUC5AC粘蛋白也都显著升高。此外,在AA患者体内,2型细胞因子水平与粘蛋白反应相关,而在AC中这种相关性不存在,这表明气道上皮细胞对炎症反应存在差异性。最后,使用新型定向分辨光学相干断层扫描在体测量AA患者气道平滑肌质量,发现其水平也显著增加。

该研究的数据表明,过敏性哮喘的发展依赖于抗原特异性CD4+T细胞固有的对2型介质的反应性以及增加的气道上皮细胞和平滑肌对2型炎症反应的敏感性。

原始出处:

Josalyn L. Cho, et al. Allergic asthma is distinguished by sensitivity of allergen-specific CD4+ T cells and airway structural cells to type 2 inflammation. Science Translational Medicine.2016. 

本文系williamhill asia 医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1652582, encodeId=667d1652582c4, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Mar 04 15:09:00 CST 2017, time=2017-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656729, encodeId=7b461656e29f8, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Aug 30 21:09:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046807, encodeId=b24b204680ecb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 07 19:09:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899094, encodeId=cac51899094cf, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 27 06:09:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067195, encodeId=9560206e195de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Dec 28 14:09:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864214, encodeId=bbc71864214e4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Mon Feb 06 19:09:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145731, encodeId=72a2145e3171, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:36 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145730, encodeId=518a145e306b, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:29 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320827, encodeId=39a9132082e33, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442607, encodeId=2781144260e93, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2017-03-04 xuyu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1652582, encodeId=667d1652582c4, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Mar 04 15:09:00 CST 2017, time=2017-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656729, encodeId=7b461656e29f8, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Aug 30 21:09:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046807, encodeId=b24b204680ecb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 07 19:09:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899094, encodeId=cac51899094cf, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 27 06:09:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067195, encodeId=9560206e195de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Dec 28 14:09:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864214, encodeId=bbc71864214e4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Mon Feb 06 19:09:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145731, encodeId=72a2145e3171, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:36 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145730, encodeId=518a145e306b, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:29 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320827, encodeId=39a9132082e33, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442607, encodeId=2781144260e93, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2017-08-30 bsmagic9140
  3. [GetPortalCommentsPageByObjectIdResponse(id=1652582, encodeId=667d1652582c4, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Mar 04 15:09:00 CST 2017, time=2017-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656729, encodeId=7b461656e29f8, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Aug 30 21:09:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046807, encodeId=b24b204680ecb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 07 19:09:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899094, encodeId=cac51899094cf, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 27 06:09:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067195, encodeId=9560206e195de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Dec 28 14:09:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864214, encodeId=bbc71864214e4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Mon Feb 06 19:09:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145731, encodeId=72a2145e3171, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:36 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145730, encodeId=518a145e306b, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:29 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320827, encodeId=39a9132082e33, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442607, encodeId=2781144260e93, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1652582, encodeId=667d1652582c4, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Mar 04 15:09:00 CST 2017, time=2017-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656729, encodeId=7b461656e29f8, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Aug 30 21:09:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046807, encodeId=b24b204680ecb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 07 19:09:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899094, encodeId=cac51899094cf, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 27 06:09:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067195, encodeId=9560206e195de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Dec 28 14:09:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864214, encodeId=bbc71864214e4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Mon Feb 06 19:09:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145731, encodeId=72a2145e3171, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:36 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145730, encodeId=518a145e306b, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:29 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320827, encodeId=39a9132082e33, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442607, encodeId=2781144260e93, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1652582, encodeId=667d1652582c4, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Mar 04 15:09:00 CST 2017, time=2017-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656729, encodeId=7b461656e29f8, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Aug 30 21:09:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046807, encodeId=b24b204680ecb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 07 19:09:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899094, encodeId=cac51899094cf, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 27 06:09:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067195, encodeId=9560206e195de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Dec 28 14:09:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864214, encodeId=bbc71864214e4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Mon Feb 06 19:09:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145731, encodeId=72a2145e3171, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:36 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145730, encodeId=518a145e306b, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:29 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320827, encodeId=39a9132082e33, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442607, encodeId=2781144260e93, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1652582, encodeId=667d1652582c4, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Mar 04 15:09:00 CST 2017, time=2017-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656729, encodeId=7b461656e29f8, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Aug 30 21:09:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046807, encodeId=b24b204680ecb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 07 19:09:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899094, encodeId=cac51899094cf, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 27 06:09:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067195, encodeId=9560206e195de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Dec 28 14:09:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864214, encodeId=bbc71864214e4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Mon Feb 06 19:09:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145731, encodeId=72a2145e3171, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:36 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145730, encodeId=518a145e306b, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:29 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320827, encodeId=39a9132082e33, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442607, encodeId=2781144260e93, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2017-02-06 qidongfanjian
  7. [GetPortalCommentsPageByObjectIdResponse(id=1652582, encodeId=667d1652582c4, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Mar 04 15:09:00 CST 2017, time=2017-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656729, encodeId=7b461656e29f8, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Aug 30 21:09:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046807, encodeId=b24b204680ecb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 07 19:09:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899094, encodeId=cac51899094cf, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 27 06:09:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067195, encodeId=9560206e195de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Dec 28 14:09:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864214, encodeId=bbc71864214e4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Mon Feb 06 19:09:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145731, encodeId=72a2145e3171, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:36 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145730, encodeId=518a145e306b, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:29 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320827, encodeId=39a9132082e33, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442607, encodeId=2781144260e93, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-10-11 知难而进

    继续关注!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1652582, encodeId=667d1652582c4, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Mar 04 15:09:00 CST 2017, time=2017-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656729, encodeId=7b461656e29f8, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Aug 30 21:09:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046807, encodeId=b24b204680ecb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 07 19:09:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899094, encodeId=cac51899094cf, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 27 06:09:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067195, encodeId=9560206e195de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Dec 28 14:09:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864214, encodeId=bbc71864214e4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Mon Feb 06 19:09:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145731, encodeId=72a2145e3171, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:36 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145730, encodeId=518a145e306b, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:29 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320827, encodeId=39a9132082e33, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442607, encodeId=2781144260e93, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-10-11 知难而进

    谢谢分享!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1652582, encodeId=667d1652582c4, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Mar 04 15:09:00 CST 2017, time=2017-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656729, encodeId=7b461656e29f8, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Aug 30 21:09:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046807, encodeId=b24b204680ecb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 07 19:09:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899094, encodeId=cac51899094cf, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 27 06:09:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067195, encodeId=9560206e195de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Dec 28 14:09:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864214, encodeId=bbc71864214e4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Mon Feb 06 19:09:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145731, encodeId=72a2145e3171, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:36 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145730, encodeId=518a145e306b, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:29 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320827, encodeId=39a9132082e33, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442607, encodeId=2781144260e93, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1652582, encodeId=667d1652582c4, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Sat Mar 04 15:09:00 CST 2017, time=2017-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656729, encodeId=7b461656e29f8, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Aug 30 21:09:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046807, encodeId=b24b204680ecb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 07 19:09:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899094, encodeId=cac51899094cf, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 27 06:09:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067195, encodeId=9560206e195de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Dec 28 14:09:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864214, encodeId=bbc71864214e4, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Mon Feb 06 19:09:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145731, encodeId=72a2145e3171, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:36 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145730, encodeId=518a145e306b, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:45:29 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320827, encodeId=39a9132082e33, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442607, encodeId=2781144260e93, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Sun Oct 09 15:09:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]

相关威廉亚洲官网

Nat Commun:特殊蛋白或可帮助开发终结过敏性哮喘症的新疗法

图片来源:medicalxpress.com 过敏症如今变得越来越普遍了,尤其是工业化国家尤为普遍,除了花粉热,过敏性哮喘如今被认为是最普遍的一种过敏症了,近日,刊登在国际杂志Nature Communications上的一项研究论文中,来自莱比锡亥姆霍兹环境研究中心(UFZ)等处的科学家通过研究发现了一种特殊蛋白,该蛋白在气道变应性炎症(allergic airway inflammat